Zion Pharma Raises $40 Million to Develop Therapies for Brain Metastases
July 28, 2021 at 05:25 AM EDT
Zion Pharma of Hong Kong raised $40 million in a Series B financing led by OrbiMed to advance its small molecule cancer drugs. Founded in 2018, Zion is based on its expertise in DMPK that allows the company to develop drugs capable of crossing the blood-brain barrier. The company's lead product in a tyrosine kinase receptor inhibitor targeting HER2 aimed at treating brain metastases accompanying HER2+ breast cancer. The candidate, ZN-A-104, has completed China and US initial trials. Zion is headquartered in Hong Kong with research operations in Shanghai and Suzhou . More details.... Share this with colleagues: // //
